Movement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment

Market Focus08-20

On August 20, GIANT BIOGENE rose 5.7% in regular trading, trading at HK$29.92/share, with turnover of HK$99.51 million. The rebound came after the stock fell nearly 6% the previous session following disappointing interim results.

On the news front, multiple institutions collectively expressed bullish views after the company reported H1 revenue of RMB 2.918 billion (down 6.3% YoY) and net profit of RMB 940 million (down 20.5% YoY) on August 18. Citi raised its target price to HK$38.4 and designated the stock as its top pick in the China cosmetics sector, citing high recovery visibility. Dongwu Securities and Guojin Securities both maintained buy ratings, arguing the darkest moment has passed, with medical aesthetics products entering commercialization and the 618 shopping festival demonstrating brand resilience. Management maintained full-year guidance of 10% revenue growth and flat net profit, implying significant acceleration in H2. Market sentiment recovered following the post-earnings oversold conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140812385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140812385","market":"us","top_or_hot":-1,"title":"Movement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment","media":"Market Focus","content":"<p><p>On August 20, GIANT BIOGENE rose 5.7% in regular trading, trading at HK$29.92/share, with turnover of HK$99.51 million. The rebound came after the stock fell nearly 6% the previous session following disappointing interim results.</p><p>On the news front, multiple institutions collectively expressed bullish views after the company reported H1 revenue of RMB 2.918 billion (down 6.3% YoY) and net profit of RMB 940 million (down 20.5% YoY) on August 18. Citi raised its target price to HK$38.4 and designated the stock as its top pick in the China cosmetics sector, citing high recovery visibility. Dongwu Securities and Guojin Securities both maintained buy ratings, arguing the darkest moment has passed, with medical aesthetics products entering commercialization and the 618 shopping festival demonstrating brand resilience. Management maintained full-year guidance of 10% revenue growth and flat net profit, implying significant acceleration in H2. Market sentiment recovered following the post-earnings oversold conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, GIANT BIOGENE rose 5.7% in regular trading, trading at HK$29.92/share, with turnover of HK$99.51 million. The rebound came after the stock fell nearly 6% the previous session following disappointing interim results.</p><p>On the news front, multiple institutions collectively expressed bullish views after the company reported H1 revenue of RMB 2.918 billion (down 6.3% YoY) and net profit of RMB 940 million (down 20.5% YoY) on August 18. Citi raised its target price to HK$38.4 and designated the stock as its top pick in the China cosmetics sector, citing high recovery visibility. Dongwu Securities and Guojin Securities both maintained buy ratings, arguing the darkest moment has passed, with medical aesthetics products entering commercialization and the 618 shopping festival demonstrating brand resilience. Management maintained full-year guidance of 10% revenue growth and flat net profit, implying significant acceleration in H2. Market sentiment recovered following the post-earnings oversold conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1140812385","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140812385","pubTimestamp":1787190681,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, GIANT BIOGENE rose 5.7% in regular trading, trading at HK$29.92/share, with turnover of HK$99.51 million. The rebound came after the stock fell nearly 6% the previous session following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物"},"translate_title":"走势警报|巨人百健常规交易上涨5.7%，多家券商在财报提振市场情绪后维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"On August 20, GIANT BIOGENE rose 5.7% in regular trading, trading at HK$29.92/share, with turnover of HK$99.51 million. The rebound came after the stock fell nearly 6% the previous session following disappointing interim results.On the news front, multiple institutions collectively expressed bullish views after the company reported H1 revenue of RMB 2.918 billion (down 6.3% YoY) and net profit of RMB 940 million (down 20.5% YoY) on August 18. Citi raised its target price to HK$38.4 and designated the stock as its top pick in the China cosmetics sector, citing high recovery visibility. Dongwu Securities and Guojin Securities both maintained buy ratings, arguing the darkest moment has passed, with medical aesthetics products entering commercialization and the 618 shopping festival demonstrating brand resilience. Management maintained full-year guidance of 10% revenue growth and flat net profit, implying significant acceleration in H2. Market sentiment recovered following the post-earnings oversold conditions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140812385","isCrawlerRequest":true}